Acacia Pharma appoints two directors to board
March 6, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing acacia pharma, christine soden, scott byrd
UK pharma firm Acacia Pharma that develops drugs for supportive care has confirmed Scott Byrd and Christine Soden have joined …
GlaxoSmithKline in major opium deal
March 5, 2015Sales and Marketing GSK, GlaxoSmithKline, Sun Pharma, opium, tasmania
GSK is to sell its opiates business to Sun Pharmaceuticals for an undisclosed amount, the two companies have announced. The …
Government lays out rare diseases plan
March 5, 2015Sales and Marketing Department of Health, NHS, UK, government, howe, rare diseases
The UK government has set out new plans to improve the lives of patients with rare diseases by 2020. The …
BMS’ Opdivo wins US lung cancer race
March 5, 2015Research and Development, Sales and Marketing BMS, Prostvac, biosciences, flexus, lung cancer, oncology, opdivo
The FDA has approved Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with metastatic squamous non-small cell lung cancer …
AbbVie buys Pharmacyclics in $21 billion deal
March 5, 2015Sales and Marketing AbbVie, Humira, Johnson and Johnson, Pharmacyclics, adalimumab, imbruvica
AbbVie has secured Californian biotech Pharmacyclics and beat Johnson & Johnson to gain control of blockbuster blood cancer therapy Imbruvica in …
Adaptimmune makes executive hires from GSK
March 5, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Adaptimmune, Adrian Rawcliffe, Rafael Amado
UK and US clinical-stage biotech firm Adaptimmune has increased its senior team with the appointment of Dr Rafael Amado as …
Eisai Alzheimer’s drug to see China review
March 4, 2015Sales and Marketing Alzheimer's, Aricept, China, Eisai, donepezil hydrochloride
Alzheimer’s drug Aricept from Eisai has been accepted for review in China to treat patients with the most severe form …
Teva to sell US manufacturing plant
March 4, 2015Manufacturing and Production, Sales and Marketing G&W Laboratories, Pennsylvania, Teva
Teva Pharmaceutical has announced that it has signed an agreement to sell a US manufacturing facility to G&W Laboratories. The …
EU widens indications for Pfizer vaccine
March 4, 2015Research and Development, Sales and Marketing EC, EMA, Pfizer, pneumococcal polysaccharide conjugate vaccine, prevenar
Pfizer has gained approval from the European Commission which has signed off on an EMA decision to recommend Prevenar 13 …
New chief executive for Takeda
March 4, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actos, Millennium, Nycomed, Takeda, Yasuchika Hasegawa, christophe weber
Japanese pharma giant Takeda has added the title of chief executive to its representative director, president and chief operating officer …
Scottish reforms proven to work says SMC
March 4, 2015Sales and Marketing NHS, NICE, Onglyza, PACE, SMC, Scotland, anne lee, scottish
The chief pharma advisor for the Scottish Medicines Consortium Anne Lee says changes to its processes have contributed to improved …
Finance director general for Department of Health retiring
March 4, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Department of Health, DoH, director general, finance, richard douglas
The Department of Health’s director general for finance and the NHS Richard Douglas is to retire at the end of …
AstraZeneca completes respiratory deal with Actavis
March 3, 2015Research and Development, Sales and Marketing Actavis, AstraZeneca, COPD, Daliresp, Tudorza Pressair, aclidinium bromide inhalation powder, respiratory, roflumilast
AstraZeneca has completed its acquisition of Dublin-headquartered firm Actavis with its branded respiratory portfolio deal worth $700 million. The agreement …
Boehringer chases approval for anti-Pradaxa drug
March 3, 2015Sales and Marketing Boehringer, Boehringer Ingelheim, Pradaxa, bleeding, dabigatran etexilate, idarucizumab
Boehringer Ingelheim is launching new drug applications for its investigational treatment to reverse the effects of its blood-thinning drug Pradaxa. …
Takeda expands in Singapore
March 3, 2015Manufacturing and Production Singapore, Takeda, biopolis, emerging markets, vaccines
Japanese pharma giant Takeda has set up new Singapore offices in the Biopolis biomedical complex with the aim of expanding …
Chiesi reprimanded again over Fostair drug
March 3, 2015Manufacturing and Production, Medical Communications, Sales and Marketing ABPI, Chiesi, PMCPA, code, formoterol/beclometason, fostair
Chiesi has been reprimanded after it breached the ABPI’s Code of Practice for its promotion of asthma inhaler Fostair. The …
NICE recommends Harvoni for hepatitis C
March 3, 2015Sales and Marketing Gilead, NICE, harvoni, hepatitis C, ledipasvir-sofosbuvir
NICE has signalled a provisional OK for Gilead’s Harvoni to be used as a treatment for hepatitis C by the …
Premise Health senior joins Nashville Health Care Council
March 3, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing nashville health care council, premise health
US worksite health and patient engagement firm Premise Health has announced that its senior VP Beth Ratliff has been selected …
ZMapp trials start in Liberia
March 2, 2015Research and Development, Sales and Marketing Africa, Ebola, Mapp, Vaccine, liberia, zmapp
Clinical trials to test the safety and efficacy of the experimental Ebola vaccine ZMapp are underway in infected parts of …
Eisai launches Lenvima in US
March 2, 2015Sales and Marketing FDA, Japan, Lenvima, US, dtc, thyroid
Japanese firm Eisai has launched its new thyroid cancer offering Lenvima in the US, making it the first country in …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
